A Phase 2 interventional study of Secondary Cytoreductive Surgery and Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer, Fallopian Tubes Cancer and Peritoneal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Completed at 11 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 16 under way, 2 of them phase 3. Ovarian Neoplasms · Memorial Sloan Kettering Cancer Center.
Among the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 12th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2013, is one of 27 in phase 2, and was the 57th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+ · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 21 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 2
First in 1991; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 36 across the 49 interventional studies, 120 across the 17 observational. Of the 64 that completed or were terminated, 18 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
14 of the studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04878094Phase 3Memorial Sloan Kettering Cancer CenterA Study of Intra-operative Imaging in Women With Ovarian Cancer | 2027-05-03 |
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT04204811Memorial Sloan Kettering Cancer CenterPrehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | 2026-12-16 |
| NCT00587886Memorial Sloan Kettering Cancer CenterEstrogen, Diet, Genetics and Endometrial Cancer | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 80 studies in Ovarian Neoplasms by Memorial Sloan Kettering Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if the investigators can improve the treatment of this type of cancer. They want to find out what effects, good and/or bad, giving heated chemotherapy into the belly, known as hyperthermic intraperitoneal chemotherapy (HIPEC), has on the patient and this type of cancer.
The goal of HIPEC is to expose any cancer left in the abdomen after surgery to high doses of chemotherapy. The chemotherapy is heated in the hope that this will make it easier for it to get into and kill the cancer cells. The drug used for HIPEC will be carboplatin, a Food and Drug Administration (FDA) approved drug for use in ovarian, fallopian tube or primary peritoneal cancer.
Inclusion Criteria:
Inclusion Criteria for Eligibility Prior to Surgery:
Inclusion Criteria for Eligibility Post-Surgery:
Exclusion Criteria:
Exclusion Criteria for Eligibility Prior to Surgery:
Exclusion Criteria for Eligibility Post-Surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
Procedure: Secondary Cytoreductive Surgery · Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) · Drug: platinum-based systemic chemotherapy postoperatively
secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
Procedure: Secondary Cytoreductive Surgery · Drug: platinum-based systemic chemotherapy postoperatively
5 cycles
6 cycles
Progression Free Survival
A proportion of patients ≥ 40%, who are without evidence of disease progression at 24 months, is considered acceptable, whereas a proportion of ≤ 25% is considered not acceptable in this patient population.
Time frame: up to 4 years
Number of Participants Evaluated for Toxicity
Study participants will be evaluated for toxicity with the NCI Common Terminology Criteria for Adverse Events version 4.0. and MSKCC Surgical Secondary Events Grading System for complications.
Time frame: 4 weeks post op
Determine the Completion Rate of Four Cycles
A secondary analysis of estimating the completion rate will be conducted. The completion rate and a 95% confidence interval will be calculated for each arm separately. Completion is defined as patients being able to complete ≥ 4 out of 5 or 6 cycles of a standard systemic chemotherapy.
Time frame: 5 years
Pharmacokinetics for HIPEC Arm Only
in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.
Time frame: 5 years
| Milestone | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Started | 49 | 50 |
| Completed | 49 | 49 |
| Not completed | 0 | 1 |
| Withdrew: Removed (started maintenance therapy) | 0 | 1 |
A proportion of patients ≥ 40%, who are without evidence of disease progression at 24 months, is considered acceptable, whereas a proportion of ≤ 25% is considered not acceptable in this patient population.
| months | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Progression Free Survival | 16.3 (7.6 to 27.9) | 28.3 (16.5 to 41.3) |
Study participants will be evaluated for toxicity with the NCI Common Terminology Criteria for Adverse Events version 4.0. and MSKCC Surgical Secondary Events Grading System for complications.
| Participants | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Number of Participants Evaluated for Toxicity | 49 | 49 |
A secondary analysis of estimating the completion rate will be conducted. The completion rate and a 95% confidence interval will be calculated for each arm separately. Completion is defined as patients being able to complete ≥ 4 out of 5 or 6 cycles of a standard systemic chemotherapy.
| Participants | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Completed assigned postoperative platinum-based chemotherapy | 46 | 46 |
| Did not complete assigned postoperative platinum-based chemotherapy | 3 | 3 |
in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.
| ug/mL | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Max unfiltrable platinum concentrations in the peritoneum | 140 ± 1.28 | — |
| Max unfiltrable platinum concentrations in the plasma | 16.7 ± 1.24 | — |
in a subset of patients randomized to receive HIPEC in the OR. In patients randomized to HIPEC, peritoneal fluid and blood samples only from MSKCC patients will be drawn before, during and after the HIPEC procedure.
| ug h/mL | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| AUC total platinum in the peritoneum | 221 ± 1.26 | — |
| AUC total platinum in the plasma | 101 ± 1.33 | — |
Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secondary Cytoreductive Surgery With HIPEC | 20/49 (40.8%) | 17/49 (34.7%) | 17/49 (34.7%) |
| Secondary Cytoreductive Surgery Without HIPEC | 21/50 (42%) | 7/50 (14%) | 19/50 (38%) |
| Event | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| Abdominal InfectionInfections and infestations | 3/49 | 0/50 |
| IleusGastrointestinal disorders | 3/49 | 0/50 |
| Abdominal painGastrointestinal disorders | 2/49 | 0/50 |
| Platelet count decreasedInvestigations | 2/49 | 0/50 |
| Pancreatic anastomotic leakInjury, poisoning and procedural complications | 2/49 | 0/50 |
| AnemiaBlood and lymphatic system disorders | 1/49 | 2/50 |
| DiarrheaGastrointestinal disorders | 1/49 | 0/50 |
| Intraoperative urinary injuryInjury, poisoning and procedural complications | 1/49 | 0/50 |
| SepsisInfections and infestations | 1/49 | 0/50 |
| Thromboembolic eventVascular disorders | 1/49 | 0/50 |
| Event | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 7/49 | 8/50 |
| Urinary tract infectionInfections and infestations | 4/49 | 0/50 |
| Abdominal infectionInfections and infestations | 2/49 | 0/50 |
| IleusGastrointestinal disorders | 2/49 | 1/50 |
| Noninfected intra-abdominal or thoracic fluid collectionGastrointestinal disorders | 1/49 | 2/50 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/49 | 2/50 |
| Wound infectionInfections and infestations | 0/49 | 2/50 |
| ColitisGastrointestinal disorders | 1/49 | 0/50 |
| Colonic obstructionGastrointestinal disorders | 1/49 | 0/50 |
| Deep vein thrombosisVascular disorders | 1/49 | 0/50 |
| Age, Continuous(years) | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC | Total |
|---|---|---|---|
| Median | 59 (39 to 74) | 58 (33 to 78) | 59 (33 to 78) |
| Sex: Female, Male(Participants) | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC | Total |
|---|---|---|---|
| Female | 49 | 50 | 99 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 44 | 43 | 87 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 39 | 45 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Region of Enrollment(Participants) | Secondary Cytoreductive Surgery With HIPEC | Secondary Cytoreductive Surgery Without HIPEC | Total |
|---|---|---|---|
| United States | 49 | 50 | 99 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2013 to primary completion in Aug 2025, 151 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 229 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 151 months is above that.
Counting every sponsor, half of 345 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Memorial Sloan Kettering Cancer Center →